The performance of companies tied to blockbuster drugs like Viagra presents a challenging investment landscape . While the initial boom of copyright, fueled by Viagra's unprecedented popularity, generated substantial returns, the loss of exclusivity in key territories has introduced considerable volatility. Investors are now grappling with the impa